As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Subscribe To Our Newsletter & Stay Updated
